报价延迟最少15分钟:2026/03/21 19:57 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
4.45 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
1.21/0.66
|
|
企业价值
262.33M
|
| 资产负债 |
|
每股账面净值
3.16
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
0.07
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel. |
